Europe ESTEVE has successfully reshaped itself in the recent years as an integrated healthcare company with two distinct growth engines: highly specialised pharmaceuticals and a global small-molecule CDMO platform, united by a shared purpose, long-term vision and a commitment to improving patients’ lives. As the US grows in relevance and investment…
Africa Diabetes is surging in Africa. But, in a continent where healthcare systems are set up to support treatments for infectious – not non-communicable – diseases, can pharma companies step up to meet demand? A new report from the Access to Medicine Foundation suggests that they can, but that new market…
Germany We believe that flexibility, analytical drive, initiative, and a detailed, hands-on mindset are more important than industry experience Peter Gerckens, CEO at PharmaSGP combines a strong background in consulting, branding, and consumer healthcare with an entrepreneurial approach to pharmaceutical growth. He emphasizes data-driven decision-making, small, agile teams, and in-house capabilities…
Global The global contract manufacturing market is booming, but fragmented. The well-established names of the CDMO space – Lonza, Thermo Fisher, WuXi AppTec, WuXi Biologics, and Samsung Biologics – account for just 15 percent of total revenues. Beyond these giants, a huge network of smaller, more specialised CDMOs are, in…
Korea Donghoon Lee outlines SK Biopharmaceuticals’ transformation into a global neuroscience player. He discusses the growth of its epilepsy profile, selective expansion into Parkinson’s disease and oncology, and acquisitions. Lee also highlights AI, targeted protein degradation, radiopharmaceutical therapy, and the company’s East–West Bridge strategy, leveraging Korean innovation and its established US…
Korea Multi-million dollar deals, world-first approvals, and a new willingness to be patient are transforming how Korea’s biotech sector does business. Korean biotech companies want to hold onto their molecules for longer. That was the message from nearly every biotech executive PharmaBoardroom spoke with in a series of recent interviews in…
USA Daniel Camardo is the President of Immedica Pharma US Inc. (Immedica), the US affiliate/subsidiary of Immedica Pharma AB, a Sweden-based rare disease company that entered the American market in 2024. Bringing together his experience building Astellas’s US presence and leading rare disease commercialization at Horizon, Camardo joined Immedica to lead…
Germany Our ambition is not simply to bring medicines to market, but to help improve the way dermatology patients are cared for As healthcare systems come under increasing pressure to deliver better outcomes with finite resources, dermatology is evolving beyond medicines alone. Kim Abbenhaus discusses how LEO Pharma is combining scientific…
Europe The goal is not only to generate scientific breakthroughs, but to ensure that these breakthroughs reach patients faster and more reliably Professor Gerd Geisslinger serves as Chair of Clinical Pharmacology at Goethe University Hospital and as Executive Director of the Fraunhofer Institute for Translational Medicine and Pharmacology (ITMP), which is…
USA We have spent the past decade building a strong foundation, investing in the market, expanding our capabilities, and assembling an exceptional team The US generics industry remains central to the healthcare system’s efforts to improve affordability, strengthen supply resilience, and expand patient access to medicines. As Cipla enters its second…
USA What motivates me is the opportunity to improve medical practice in a meaningful way, rather than simply bringing another product to market In an industry where genuine differentiation is becoming harder to find, Barry Quart sees in rademikibart the potential to address a longstanding unmet need in acute respiratory care.…
Korea Korea has something that very few countries can claim: high-quality healthcare data at genuine population scale JK Lee, Vice President of the Korea Pharmaceutical and Bio-Pharma Manufacturers Association (KPBMA), outlines Korea’s transition from a generics-driven industry to a global innovation hub. He highlights the government’s strategic support, a growing pipeline…
See our Cookie Privacy Policy Here